Tabimorelin

• CAT Number: R012581
• CAS Number: 193079-69-5
• Molecular Formula: C32H40N4O3
• Molecular Weight: 528.697
• Purity: ≥95%
• Storage: Room temperature
• IUPAC Name: (E)-5-amino-N,5-dimethyl-N-[(2R)-1-[methyl-[(2R)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide
• InChI: InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
• InChIKey: WURGZWOTGMLDJP-ZCYANPAGSA-N
• SMILES: CC(C)(CC=CC(=O)N(C)C(CC1=CC2=CC=CC=C2C=C1)C(=O)N(C)C(CC3=CC=CC=C3)C(=O)NC)N

Tabimorelin is a growth hormone releasing factor agonist potentially for the treatment of growth hormone deficit. Tabimorelin is a drug which acts as a potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue, mimicking the effects of the endogenous peptide agonist ghrelin as a stimulator of growth hormone (GH) release.

Reference

1:Adipogenic and orexigenic effects of the ghrelin-receptor ligand tabimorelin are diminished in leptin-signalling-deficient ZDF rats. Holm AM, Johansen PB, Ahnfelt-Rønne I, Rømer J.Eur J Endocrinol. 2004 Jun;150(6):893-904. PMID: 15191361 Free Article2:A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. Zdravkovic M, Olsen AK, Christiansen T, Schulz R, Taub ME, Thomsen MS, Rasmussen MH, Ilondo MM.Eur J Clin Pharmacol. 2003 Feb;58(10):683-8. Epub 2003 Feb 6. PMID: 12610745